LifeCycle Pharma announces positive data from LCP-AtorFen Phase I clinical program

Announcement no. 2/2007

To OMX Nordic Exchange.	Hørsholm, 26 February 2007



LifeCycle Pharma announces positive data from LCP-AtorFen 
Phase I clinical program

Summary: LifeCycle Pharma successfully completes Phase I LCP-AtorFen clinical
program, and expects to initiate Phase II clinical program in Q2 2007 

LifeCycle Pharma A/S (OMX:LCP) announced today positive results from the
company's Phase I clinical program with LCP-AtorFen, a fixed-dose combination
product of atorvastatin and fenofibrate for the treatment of high cholesterol
levels. The program was a comparative pharmacokinetic study between LCP-AtorFen
and Lipitor® and Tricor® and was carried out in Canada. LCP-AtorFen has a
convenient single pill once-daily dosing regime and is without food effect. 

The Phase I program showed LCP-AtorFen was safe and well-tolerated and that the
product had a similar rate and extent of absorption compared to Lipitor® and
Tricor®. The company is now preparing for the initiation of a Phase II program,
expected to start during Q2 of 2007. 

“We are pleased with the successful outcome of the Phase I program, and are on
track to start our Phase II program with LCP-AtorFen as planned,” said Dr.
Flemming Ørnskov, President and CEO of LifeCycle Pharma.  “This positive result
confirms our confidence in the application of our MeltDose® technology for
producing convenient fixed-dose combination products of two different active
ingredients within a single tablet,” added Dr. Ørnskov. 

About LCP-AtorFen 
LCP-AtorFen is our proprietary product candidate combining atorvastatin (the
active ingredient of Lipitor) and the lowest dose of fenofibrate without food
effect. LCP-AtorFen is designed to be a powerful and safe treatment of high
cholesterol levels, addressing three primary cardiovascular risk factors: low
density lipoprotein (LDL), high density lipoprotein 
(HDL) and triglycerides (TG). In the United States alone, sales of atorvastatin
and fenofibrate were approximately €7.5 billion in 2005, an increase of 12%
over 2004. The company's Phase I clinical program was initiated in October
2006. 

For further information please contact:
LifeCycle Pharma A/S
Rachel Curtis Gravesen
VP Investor and Public Relations
Tel. +45 36 13 29 17
Mobile: +45 25 12 62 60

--oo0oo---


About LifeCycle Pharma:
LifeCycle Pharma is an emerging pharmaceutical company with a broad and late
stage product pipeline in therapeutic areas of cholesterol management,
hypertension and organ transplant. LifeCycle Pharma's most advanced product has
been filed with the U.S. FDA and is expected to enter the US market in the
first quarter of 2008. LifeCycle Pharma's product candidates are proprietary
and designed to improve the quality of existing drugs by enhancing the release
and absorption of drugs in the human body. LifeCycle Pharma's proprietary
technology platform, MeltDose® technology, offers lower dosing, reduced side
effects and improved safety and patient compliance as well as reduced product
development time and production costs. LifeCycle Pharma has formed several
partnerships with major pharmaceutical companies and is clinically developing
product candidates within a number of areas, including cholesterol management,
hypertension and organ transplant. LifeCycle Pharma is listed on the OMX Nordic
Exchange under the trading symbol (LCP). Please visit www.lcpharma.com for
further information about LifeCycle Pharma A/S.